Valuation: Armata Pharmaceuticals, Inc.

Market Cap 189M 166M 155M 142M 267M 18.13B 270M 1.84B 718M 8.95B 710M 694M 30.94B P/E 2026 *
-1.35x
P/E 2027 * -3.84x
Enterprise Value 189M 166M 155M 142M 267M 18.13B 270M 1.84B 718M 8.95B 710M 694M 30.94B EV / Sales 2026 *
85.9x
EV / Sales 2027 * 68.7x
Free-Float
31.49%
Yield 2026 *
-
Yield 2027 * -
1 day+10.52%
1 week+1.78%
Current month-20.52%
1 month-30.41%
3 months-53.18%
6 months-21.85%
Current year-17.99%
1 week 4.36
Extreme 4.36
5.5
1 month 3.48
Extreme 3.48
7.33
Current year 3.48
Extreme 3.48
14.98
1 year 2.35
Extreme 2.35
16.34
3 years 0.9
Extreme 0.8981
16.34
5 years 0.83
Extreme 0.8311
16.34
10 years 0.83
Extreme 0.8311
16.34
Manager TitleAgeSince
Chief Executive Officer 70 11/07/2023
Director of Finance/CFO 42 16/08/2024
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 62 09/05/2019
Director/Board Member 66 12/02/2020
Director/Board Member 51 12/02/2020
Date Insider Type Main position Quantity % Market Cap.
10/07/26 Tax

Chief Executive Officer

-14,041 0.0382%
24/04/26 Free

Director

51,280 0.1400%
14/03/26 Tax

Public Communications Manager

1,030 0.0028%
Change 5-day change 1-year change 3-year change Capi.($)
+10.52%+1.78%+115.48%+106.83% 189M
-0.66%+3.21%+53.30%+72.82% 56.19B
-0.27%+0.35%+40.26%+79.88% 54.83B
+1.97%-1.16%-21.00%-13.25% 23.04B
-2.05%-2.14%+0.75%+413.38% 22.7B
-0.21%-0.62%+20.56%-10.90% 20.23B
-1.10%+1.65%+25.74%-30.44% 17.83B
-0.97%-0.59%+33.12%+550.67% 15.65B
+5.29%+1.70%+185.09%+333.94% 15.24B
+0.79%+0.50%+22.39%+184.74% 14.03B
Average +1.33%+0.97%+47.57%+168.77% 23.99B
Weighted average by Cap. +0.00%+1.07%+38.70%+137.99%

Financials

2026 *2027 *
Net sales 2.2M 1.93M 1.8M 1.65M 3.1M 211M 3.15M 21.4M 8.36M 104M 8.26M 8.08M 360M 2.75M 2.42M 2.25M 2.07M 3.88M 264M 3.93M 26.75M 10.45M 130M 10.32M 10.1M 450M
Net income -172M -151M -141M -129M -243M -16.49B -246M -1.67B -653M -8.14B -645M -631M -28.13B -66.35M -58.33M -54.3M -49.86M -93.63M -6.36B -94.87M -645M -252M -3.14B -249M -244M -10.86B
Net Debt - -
Logo Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.
Employees
61
Date Price Change Volume
27/07/26 $5.150 +10.52% 96,036
24/07/26 $4.660 -10.73% 63,494
23/07/26 $5.220 -0.38% 102,209
22/07/26 $5.240 +1.55% 127,648
21/07/26 $5.160 +1.98% 270,136
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.150USD
Average target price
17.50USD
Spread / Average Target
+239.81%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARMP Stock